Algernon Pharmaceuticals Inc (AGNPF)

[carramrod]

Excited to see what comes of these trials/liking the science behind Ifenprodil. Sorry if this has already been posted. An old Breahtec investor who has stuck around.


https://www.utdallas.edu/news/health-medicine/nerve-cells-lungs-covid-19-2020/

“There’s a striking increase in NMDA (N-methyl-D-aspartate) receptors in immune cells in the lungs that is much different than you see in other diseases,” Price said. “It suggests that maybe the neurons there can communicate with the immune cells via glutamate, the neurotransmitter that NMDA receptors respond to. Interrupting this interaction might lessen the damaging effect.”


http://www.pharmabiz.com/PrintArticle.aspx?aid=129734&sid=2

"NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.

The company believes NP-120 can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients."